PBTH), which develops proteins for therapeutic uses, today reported publication of a preclinical study in the latest online edition of "Endocrinology." The study shows that the human growth hormone linked to Prolor's carboxyl terminal peptide (CTP) technology has significantly increased bioactivity compared with the commercially available human growth hormone. The study, written by Prolor's researchers, will also be included in the September print edition of "Endocrinology."
The company is developing CTP to provide growth hormone deficient adults and children with growth hormone therapy that requires only once-weekly or bi-monthly injections, rather than the multiple injections per week required by current human growth hormone regimens.
Prolor recently initiated a Phase II clinical trial of CTP, following a successful Phase I trial that suggested that CTP, in addition to meeting all safety and tolerability requirements, could potentially be effective when injected just twice per month.
Prolor's chief scientific officer and lead author of the study Dr. Fuad Fares said "The publication of this study in "Endocrinology,." considered to be one of the most authoritative biomedical research journals in the world, further validates the growing body of clinical and preclinical data supporting the ability of CTP technology to significantly extend the half-life and duration of action of therapeutic proteins,"
He added, "Therapeutic proteins are increasingly important treatments for a variety of diseases, and we believe the demonstrated ability of CTP technology to reduce the frequency of required injections could provide important benefits to the many patients who depend on these drugs. We look forward to completing the ongoing Phase II trial of hGH-CTP and anticipate initiating Phase III studies during 2011."
Prolor's share closed at $5.95 on AMEX on Friday, giving a market cap of $275.14 million.
Published by Globes, Israel business news - www.globes-online.com - on August 2, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010